After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. | ...

Amgen (AMGN) announced a $900M expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total ...

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...